Drug-induced lenticular opacity and accumulation of cholesterol-related substances in the lens cortex of dogs.


Journal

The Journal of toxicological sciences
ISSN: 1880-3989
Titre abrégé: J Toxicol Sci
Pays: Japan
ID NLM: 7805798

Informations de publication

Date de publication:
2020
Historique:
entrez: 3 4 2020
pubmed: 3 4 2020
medline: 23 9 2020
Statut: ppublish

Résumé

TP0446131, developed as an antidepressant agent, was found to cause lenticular opacity in a 13-week repeated-dose study in dogs. Histopathologically, the lenticular opacity was observed as a degeneration of the lens fibers, characterized by irregularity in the ordered arrangement of the fibers which is necessary to maintain the transparency of the lens, and was considered to manifest clinically as cataract. To evaluate the development mechanism of the lenticular opacity, the chemical constituents of the lens, which is known to be associated with the development of cataract, were examined. The results of liquid chromatography-tandem mass spectrometry analysis revealed an increase in the amplitudes of 3 unknown peaks in a dose- and time-dependent manner in the lens, with no remarkable changes in the other chemical components tested. In addition, the content of cholesterol, alterations of which have been reported to be associated with cataract, remained unchanged. The mass spectral data and chromatographic behavior of the 3 peaks indicated that these peaks corresponded to sterol-related substances, and that one of them was 7-dehydrocholesterol, a precursor of cholesterol biosynthesis. This finding suggested that TP0446131 exerts some effects on the cholesterol biosynthesis pathway, which could be involved in the development of the cataracts. Furthermore, increases in the levels of these sterol-related substances were also detected in the serum, and were, in fact, noted prior to the onset of the cataract, suggesting the possibility that these substances in the serum could be used as potential safety biomarkers for predicting the onset of cataract induced by TP0446131.

Identifiants

pubmed: 32238695
doi: 10.2131/jts.45.201
doi:

Substances chimiques

Antidepressive Agents 0
Biomarkers 0
Dehydrocholesterols 0
7-dehydrocholesterol BK1IU07GKF

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-218

Auteurs

Hiroshi Iwasaki (H)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Masaki Wakamatsu (M)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Kazunari Sugihara (K)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Kyohei Kamio (K)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Satoshi Tsuji (S)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Junya Morita (J)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Yasuhiro Kurihara (Y)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Tomoko Izumi (T)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Tomohiro Nishimoto (T)

Pharmacokinetics Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Kohnosuke Kinoshita (K)

Pharmacokinetics Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Yutaka Nakanishi (Y)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Minoru Sasaki (M)

Drug Safety Laboratories, Research Center, Taisho Pharmaceutical Co., Ltd.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH